Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound.

Autor:	Harnden K; University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, UK kate.harnden@nhs.net., Di Matteo A; University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, UK.; Leeds Teaching Hospitals NHS Trust, Leeds, UK., Howell K; Leeds Teaching Hospitals NHS Trust, Leeds, UK., Mankia K; University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, UK.; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Jazyk:	angličtina
Zdroj:	BMJ case reports [BMJ Case Rep] 2024 Apr 24; Vol. 17 (4). Date of Electronic Publication: 2024 Apr 24.
DOI:	10.1136/bcr-2023-258706
Abstrakt:	Immune checkpoint inhibitors have revolutionised the treatment of cancer. While very effective, they commonly cause a wide spectrum of immune-related adverse events. These immune-related adverse events can be fatal and often have significant effects on quality of life. They therefore require prompt recognition and management. We report the case of a woman presenting with widespread joint pain and stiffness 6 hours after her first pembrolizumab infusion. She had no joint swelling on physical examination but an ultrasound scan revealed widespread musculoskeletal inflammation, confirming the diagnosis of inflammatory arthritis. To the best of our knowledge, this is the fastest reported inflammatory arthritis onset following immune checkpoint inhibitor treatment. It highlights the importance of timely imaging in patients on immune checkpoint inhibitors who present with new non-specific musculoskeletal pain. Her symptoms improved dramatically with intramuscular triamcinolone injection. Competing Interests: Competing interests: There is no specific grant for this research from any funding agency. KHa, ADM and KHo have no conflicts of interest to declare. KM has grants from Lilly, Gilead and Serac Life Sciences. KM has consulting fees from Serac Life Sciences and Lilly. KM has payment for lectures from AbbVie, Galapagos and UCB. KM has support for attending meetings from AbbVie. (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu